Current drug delivery最新文献

{"title":"Electrospun Nanofiber Films Containing Hesperidin and Ofloxacin for the Inhibition of Inflammation and Psoriasis: A Potential In vitro Study.","authors":"Thirumal V, Jerad Suresh A, Sujatha K, Alan Mathew Punnoose, Dhanush R, Sowmya C","doi":"10.2174/0115672018390944250505120443","DOIUrl":"https://doi.org/10.2174/0115672018390944250505120443","url":null,"abstract":"<p><strong>Introduction: </strong>Nanofiber (NF) films have emerged as a promising alternative for treating psoriasis. Based on their specific characteristics, they have distinguished themselves from other topical dosage forms, such as hydrogels, foams, and sponges. This research focuses on making biocompatible and biodegradable nanofibers out of Polyvinyl Alcohol (PVA) and gelatin, by adding Hesperidin (HPN) and Ofloxacin (OFX) as medicines.</p><p><strong>Methods: </strong>HPN-OFX-integrated nanofiber (HPN-OFXNF) films were prepared using the electrospinning technique. Subsequently, the surface morphology, entrapment efficiency, in vitro drug diffusion, as well as antimicrobial, anti-inflammatory, and anti-psoriasis properties were investigated.</p><p><strong>Results: </strong>Scanning Electron Microscopy (SEM) analysis revealed that the produced nanofibers exhibited smooth surfaces through diameters from 50.67 to 114.4 nm. Most of the nanofibers exhibited a moderate entrapment efficacy of around 69.3 ± 1.8% for OFX and 45.63 ± 1.6% for HPN. In vitro HPN and OFX release showed a biphasic trend of an early burst trailed through a sustained pattern after approximately 48 h, depending on the surface area and diameter of the fibers. In vitro, antimicrobial testing of the films demonstrated higher inhibition zones (24.89 ± 3.2 and 42.46 ± 4.4 mm) against E. coli and S. aureus. The anti-inflammatory assay indicated that the activity was doubled with HPN-OFX-loaded nanofibers, compared to pure HPN. Moreover, the NF films had stronger antioxidant activities with a higher scavenging of DPPH and hydroxyl radicals. HPN-OFXNF films have been demonstrated to possess stronger antiproliferative activities than pure HPN on human keratinocytes in follow-up experiments showing an IC50 value of 64.6 ± 3.4 μg/mL.</p><p><strong>Conclusion: </strong>This therapy, which includes a combined anti-inflammatory and antibacterial treatment strategy with an innovative drug delivery system, has proven to be a promising development in treating psoriasis.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking the Power of Electrospinning: A Review of Cutting-Edge Polymers and their Impact on Scaffold Design and Performance.","authors":"Tanmoy Ghosh, Aditya Nemadea, Vineeth Kumar K, Shruthi N, Shwetha V, Pushpalatha C","doi":"10.2174/0115672018366586250402144057","DOIUrl":"https://doi.org/10.2174/0115672018366586250402144057","url":null,"abstract":"<p><p>Electrospun scaffolds are pivotal in tissue engineering due to their ability to mimic the Extracellular Matrix (ECM). Despite their potential, challenges such as, two-dimensional structure, limited load bearing capacity, and low mechanical strength restrict their application. This review explores advancements in electrospinning techniques and materials, highlighting methods like coaxial electrospinning, which enables the encapsulation of therapeutic agents, and the integration with 3D printing to create hybrid scaffolds with improved cell infiltration. Characterization techniques assessed by different researchers, such as scaffold morphology, mechanical properties, and biocompatibility, show that scaffolds with high spatial interconnectivity and controlled alignment enhance cell orientation and migration. Innovations in smart polymers and stimuli-responsive materials have furthered scaffold functionality. While recent advancements address some limitations, issues with scalability and production uniformity remain. Future research should optimize fabrication parameters and explore novel materials to enhance scaffold performance, requiring collaborative efforts and technological innovations to expand their practical applications in tissue engineering and regenerative medicine.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revolutionizing Personalized Medicine with 4D Printing in Drug Delivery.","authors":"Nandini Sharma, Yukta Garg, Amandeep Singh","doi":"10.2174/0115672018388762250414114651","DOIUrl":"https://doi.org/10.2174/0115672018388762250414114651","url":null,"abstract":"<p><p>4D printing is an improvement over the traditional 3D printing technique involving the application of dynamic materials that change with the environmental conditions, including temperature, humidity, and pH. This technology holds great promise for drug development to create effective and personalized drug delivery systems. Different from conventional technologies, 4D printed systems can control the administration rate of drugs depending on the internal environment, thus enhancing the effectiveness of treatments and considering adverse effects at the same time effectively. 4D printing contributes to the creation of smart materials for use in vaccines, implants, and other devices that respond to body signals in real-time. However, several hurdles persist in the synthesis and fabrication of these materials as well as their regulatory approval. This technology represents the future of drug manufacturing, emphasizing patient-specific care and providing a more effective, efficient, and adaptive approach to therapeutic delivery.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidneys Toxicity and Biodistribution of Albumin-Based Gold and Silver Nanoclusters.","authors":"Hussein Alhawari, Sameeha AlShelleh, Nisreen Abu Shahin, Mahmoud Alkawareek, Reem Abbasi, Maryam K El-Zubi, Rania Mahafdeh, Karem H Alzoubi, Alaaldin M Alkilany","doi":"10.2174/0115672018369974250321004041","DOIUrl":"https://doi.org/10.2174/0115672018369974250321004041","url":null,"abstract":"<p><strong>Background: </strong>The interaction of the kidneys with nanoparticles is a fundamental issue that accelerates the proper design of efficient and safe nanotherapeutics. The present study aimed to establish the kidney toxicity and the biodistribution profile of novel gold and silver nanocluster formulations.</p><p><strong>Methods: </strong>Gold and silver nanoclusters were synthesized in an albumin template to probe their kidney- nano interaction. The interaction was performed on healthy animals to unveil the toxicity of nanoclusters on kidney tissue.</p><p><strong>Results: </strong>Albumin-based gold nanoclusters (BSA-AuNCs) and albumin-based silver nanoclusters (BSA-AgNCs), exhibited comparable core size (2.2±1.3 nm and 2.5±1.6 nm, respectively) and hydrodynamic diameter (11.3±2.1 nm for BSA-AuNC and 10.7±1.9 nm for BSA-AgNC) indicating similarity in their core and overall sizes. Zeta potential measurements demonstrated a comparable surface charge between BSA- AuNC (18.1±3.2 mV) and BSA- AgNC (20.1±3.6 mV), which closely resembled the surface charge of albumin in water (20.7±3.5 mV). Upon administration to rats via intravenous route, ICP-OES measurements showed a significant silver and gold nanocluster accumulation in various vital organs with unequal distribution patterns. BSA-AgNC exhibited higher concentrations in the liver and spleen, while BSA-AuNC showed predominant accumulation in the liver and kidneys. However, the administered BSA-AgNC induced more renal damage than BSA- AuNCs.</p><p><strong>Conclusion: </strong>The identified renal toxicity linked to BSA-AgNCs, despite their lower kidney accumulation than BSA-AuNCs, illuminates the intricate interplay between nanoparticle biodistribution and toxicity. This underscores the significance of considering the core metal type in nanoparticle design and evaluation. Further investigation is needed to clarify the underlying molecular mechanisms of the observed biodistribution and toxicity.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of Luteolin and Silibinin Has Hepatoprotective Effects on Rats' Liver Fibrosis Induced by Thioacetamide.","authors":"Zaenah Z Alamri, Rahaf F Aharthi, Sahar J Melebary","doi":"10.2174/0115672018365305250321001815","DOIUrl":"https://doi.org/10.2174/0115672018365305250321001815","url":null,"abstract":"<p><strong>Introduction: </strong>A serious public health condition called liver fibrosis can cause cirrhosis, cancer, and even patient death.</p><p><strong>Method: </strong>This study sought to determine if Luteolin [LUT] and Silibinin [SBN] could protect rats against oxidative stress and liver fibrosis caused by thioacetamide [TAA] over three weeks, as well as any potential mechanisms of action. There will be 49 adult Wistar albino rats utilized, split up into 7 groups: [G1] Negative control, [G2] Positive control, [G3] LUT+TAA, [G4] SBN+TAA, [G5] mix LUT+ SBN, [G6] LUT+SBN with TAA, [G7] LUT+SBN then TAA, and so. Liver function tests and oxidative stress markers were measured after the experiment. The liver underwent microscopic inspection. Rats given TAA treatment had significantly higher liver enzymes than control; yet, albumin [ALB], total protein [TP], superoxide dismutase [SOD], and reduced glutathione [GSH] significantly decreased.</p><p><strong>Results: </strong>Following three weeks of TAA exposure, liver sections revealed hepatocytic damage and fibrosis. Oxidative stress, histological alterations, and alterations in liver function were all lessened in TAA rats administered with LUT, SBN, or both.</p><p><strong>Conclusion: </strong>The combined hepatoprotective benefits of LUT and SBN prevented TAA-induced biochemical and histological alterations in rat liver, acting in concert with each other.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in Nanostructured Lipid Carriers for Colorectal Cancer Treatment: A Comprehensive Review.","authors":"Riya Patel, Shailvi Shah, Sheetal Acharya, Gayatri Patel, Shreeraj Shah, Bhupendra G Prajapati","doi":"10.2174/0115672018340391250321041056","DOIUrl":"https://doi.org/10.2174/0115672018340391250321041056","url":null,"abstract":"<p><p>As colorectal cancer is the third most common cancer globally, this study aimed to improve colorectal cancer treatment using nanostructured lipid carriers (NLCs) for drug delivery by overcoming the current drawbacks, improving therapeutic effectiveness, achieving site-specific delivery, and implementing controlled drug administration to mitigate systemic side effects. Based on the literature, it has been observed that the optimal drug size and zeta potential range depend on the drug formulation's targets and features. These ranges are determined through optimization and characterization. The particle size ranges from 10 to 200 manometers, and the zeta potential values range from -30 mV to +30 mV. Optimal formulations should have uniform spherical morphology and compatibility with biological entities. This paper provides an in-depth analysis of nanocarrier research and findings. This article offers a thorough synopsis of the latest research and findings on nanocarriers, offering a valuable understanding of their development.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biocompatibility Evaluation of a Dexamethasone Mucoadhesive Nanosystem: Preclinical and Preliminary Clinical Evaluations.","authors":"Graciela Lizeth Pérez-González, Luis Jesús Villarreal-Gómez, Lucia Margarita Valenzuela-Salas, Edgar Ramiro Méndez-Sánchez, Jose Manuel Cornejo-Bravo","doi":"10.2174/0115672018356821250323083549","DOIUrl":"https://doi.org/10.2174/0115672018356821250323083549","url":null,"abstract":"<p><strong>Introduction: </strong>There is a strong need for drug delivery systems that are both highly compatible with biological tissues and effective when used in the oral mucosa. While gels, creams, or ointments are currently employed for this purpose, their oral bioavailability is constrained by the limited contact time with mucosal tissue.</p><p><strong>Method: </strong>In response to this challenge, we developed and evaluated the efficacy of a multilayer mucoadhesive system incorporated with Dexamethasone Sodium Phosphate (DEX-P) for oral mucosal delivery. An electrospun multilayer system was created and subjected to biocompatibility and efficiency testing through both in vitro and ex vivo approaches, finally culminating in an acceptability trial in healthy human volunteers. The multilayer system was created using Poly-Vinyl Pyrrolidone (PVP) and Poly ε-Caprolactone (PCL) as a polymeric base and Polycarbophil (NOVEON® AA-1, PCF) serving as an adhesion enhancer to facilitate the unidirectional release of Dexamethasone Sodium Phosphate (DEX-P).</p><p><strong>Result: </strong>The nanofibers matrices underwent morphological characterization by Scanning Electron Microscopy (SEM), and DEX-P release was evaluated using ex vivo porcine mucosa, yielding promising results. In vitro cytotoxicity was evaluated through the MTT assay, employing HFF-1 cells. The cell viability ranged from 78 to 96%, suggesting the safety of the polymers used. The tested dose range of DEX on cell lines did not decrease below 75%, indicating its safety in terms of in vivo cytotoxicity. Biocompatibility was evaluated on animal models, with no considerable tissue damage observed.</p><p><strong>Conclusion: </strong>Human in vivo studies demonstrated prolonged adhesion and a favorable perception of the system.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144040455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Transdermal Drug Delivery with Novasome Nanocarriers: A Quality by Design (QbD) Framework.","authors":"Prabhjot Kaur, Priyanka Kriplani","doi":"10.2174/0115672018367563250318083438","DOIUrl":"https://doi.org/10.2174/0115672018367563250318083438","url":null,"abstract":"<p><p>A revolutionary encapsulation-based drug delivery technique called novasome technology outperforms conventional liposome systems in terms of effectiveness and efficiency. It is comprised of free fatty acid, cholesterol, and surfactant, which combine to yield better vesicle properties for medication administration. Numerous research endeavors have examined the ideal blend of surfactant types, free fatty acids, and their proportions, along with the formulation elements that might substantially impact the vesicle properties. It has been shown that novasome technology may be used to deliver various drugs, such as vaccines, niflumic acid, zolmitriptan, and terconazole. To develop the most effective novasomal formulations with significant drug loading and nano-metric form, it is important to find the appropriate ratio between core components along with critical manufacturing process determinants. Understanding the interplay between these factors requires applying Quality by Design (QBD) in combination with Design of Experiments (DoE). These may be applied for both scale-up and lab-scale applications. This manuscript includes a detailed view of novasomes and the involvement of QBD.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision Drug Delivery to the Liver: A Nanoparticle Approach.","authors":"Krishna Yadav, Ajazuddin, Mukesh Sharma, Kushagra Nagori, Parag Jain, Sunita Minz, Manju Rawat Singh, Deependra Singh, Madhulika Pradhan","doi":"10.2174/0115672018350438250311045745","DOIUrl":"https://doi.org/10.2174/0115672018350438250311045745","url":null,"abstract":"<p><p>The global burden of Chronic Liver Diseases (CLDs) is escalating, with increasing prevalence and mortality. Various conditions ranging from fibrosis, cirrhosis, and hepatocellular carcinoma are associated with conditions such as toxin accumulation, viral infections, and metabolic derangements. In this already difficult context, the emergence of metabolic dysfunction-associated steatotic liver disease and steatohepatitis complicated the picture even further. While there has been much advancement in medical research, there is currently no standard cure; hence, the best treatment options are limited, providing a rising need for new therapeutic approaches. Nanoparticle drug delivery systems represent a promising avenue, providing targeted delivery and enhanced therapeutic effectiveness. Nanosystems can protect therapeutic agents from degradation, evade rapid clearance mechanisms, and target drugs directly to a specific hepatic cell type. However, the complex architecture of the liver presents challenges for these therapies, including the need to precisely target individual cells and retain the stability of nanoparticles within the hepatic microenvironment. This review presents recent advances in nanoparticle and targeted ligands-based technologies. These technologies help to navigate barriers associated with similar therapies. As these challenges are addressed, nanotechnological advancements could potentially lead to a major revolution in the treatment of CLDs, paving the way for improved management strategies and providing new hope for affected individuals worldwide.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Antibiotic-Loaded PEGylated Xerogels of Acidified Chitosan for Periodontal Diseases.","authors":"Farjad Zafar, Muhammad Ali Sheraz, Syed Abid Ali, Maryam Riaz, Sofia Ahmed, Zubair Anwar","doi":"10.2174/0115672018377472250326061736","DOIUrl":"https://doi.org/10.2174/0115672018377472250326061736","url":null,"abstract":"<p><strong>Objectives: </strong>The primary aim of this study was to develop an effective treatment strategy for periodontal diseases that maximizes therapeutic effects while minimizing systemic adverse effects. Specifically, the study focused on creating a xerogel-based localized drug delivery system for the slow release of doxycycline hyclate (DH) to treat periodontal disease.</p><p><strong>Methods: </strong>Xerogels were prepared using the solvent casting method, with the solvent being evaporated slowly at ambient conditions. The prepared DH xerogels underwent comprehensive characterization to assess their in-silico compatibility, pharmacokinetics, and physicochemical properties. The properties studied included drying time and rate, thickness, moisture content, swelling index, organoleptic properties, scanning electron microscopy, FTIR spectroscopy, differential scanning calorimetry, drug release and kinetics, and antibacterial activity.</p><p><strong>Results: </strong>In-silico studies demonstrated compatibility between the ingredients, indicating minimal adverse effects on the body. The analysis revealed hydrogen bonding between the drug and polymers, changing the drug's crystallization characteristics to an amorphous form. The release profiles of DH from the xerogels indicated a slow release, ranging from 29.42% to 66.30% over 10 hours, following the Hopfenberg model.</p><p><strong>Conclusion: </strong>The findings of this study suggest that the formulated xerogels are well-suited for periodontal applications. The slow-release profile of DH from the xerogels offers a promising approach for localized treatment of periodontal disease, reducing the risk of systemic adverse effects. This data is valuable for dental practitioners and pharmaceutical formulators, providing a new avenue for enhancing periodontal disease treatment.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143733849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}